Duojian C. Kong

It is well known of the requirement of HLA-DQ2/8 for developing CeD, but only 3% of DQ2/8 carriers have CeD. Therefore, a systemic approach is required to improve the clinical utility of genetic testing and providing a better genetic risk stratification…